EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Biofilm antimicrobial susceptibility testing: where are we and where could we be going?

Tom Coenye iD

Clinical Microbiology Reviews · 20.12.2023 · 36 (4)

DOI: 10.1128/cmr.00024-23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 20.12.2023. Verfasst von Tom Coenye. Beteiligte Einrichtung: Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Biofilms. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 245 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our knowledge about the fundamental aspects of biofilm biology, including the mechanisms behind the reduced antimicrobial susceptibility of biofilms, has increased drastically over the last decades. However, this knowledge has so far not been translated into major changes in clinical practice. While the biofilm concept is increasingly on the radar of clinical microbiologists, physicians, and healthcare professionals in general, the standardized tools to study biofilms in the clinical microbiology laboratory are still lacking; one area in which this is particularly obvious is that of antimicrobial susceptibility testing (AST). It is generally accepted that the biofilm lifestyle has a tremendous impact on antibiotic susceptibility, yet AST is typically still carried out with planktonic cells. On top of that, the microenvironment at the site of infection is an important driver for microbial physiology and hence susceptibility; but this is poorly reflected in current AST methods. The goal of this review is to provide an overview of the state of the art concerning biofilm AST and highlight the knowledge gaps in this area. Subsequently, potential ways to improve biofilm-based AST will be discussed. Finally, bottlenecks currently preventing the use of biofilm AST in clinical practice, as well as the steps needed to get past these bottlenecks, will be discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBiofilmsHumansMicrobial Sensitivity Tests

Stichwörter der Autor:innen

biofilmsusceptibility testing

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

ORCID-Profile: Tom Coenye

Zitieren

APA

Coenye, T. (2023). Biofilm antimicrobial susceptibility testing: where are we and where could we be going?. Clinical Microbiology Reviews, 36(4). https://doi.org/10.1128/cmr.00024-23

Vancouver

Coenye T. Biofilm antimicrobial susceptibility testing: where are we and where could we be going?. Clinical Microbiology Reviews. 2023;36(4). doi:10.1128/cmr.00024-23

BibTeX
@article{Coenye2023,
  author = {Coenye, Tom},
  title = {Biofilm antimicrobial susceptibility testing: where are we and where could we be going?},
  journal = {Clinical Microbiology Reviews},
  year = {2023},
  volume = {36},
  number = {4},
  doi = {10.1128/cmr.00024-23}
}
Kostenlos starten →